305 related articles for article (PubMed ID: 28669865)
21. Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker.
Lei B; Zhang XY; Zhou JP; Mu GN; Li YW; Zhang YX; Pang D
Tumour Biol; 2016 Nov; 37(11):14757-14764. PubMed ID: 27629143
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
23. [Molecular signatures of breast cancer: What clinical utility?].
Delaloge S; Saghatchian M; Ghouadni A; Fekih M; André F
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S102-5. PubMed ID: 26118866
[TBL] [Abstract][Full Text] [Related]
24. Grading breast cancer tissues using molecular portraits.
Olsson N; Carlsson P; James P; Hansson K; Waldemarson S; Malmström P; Fernö M; Ryden L; Wingren C; Borrebaeck CA
Mol Cell Proteomics; 2013 Dec; 12(12):3612-23. PubMed ID: 23982162
[TBL] [Abstract][Full Text] [Related]
25. RNA-Seq accurately identifies cancer biomarker signatures to distinguish tissue of origin.
Wei IH; Shi Y; Jiang H; Kumar-Sinha C; Chinnaiyan AM
Neoplasia; 2014 Nov; 16(11):918-27. PubMed ID: 25425966
[TBL] [Abstract][Full Text] [Related]
26. Integrating breast cancer genetics into clinical practice.
Mukherjee A; Rakha EA
Womens Health (Lond); 2012 Jan; 8(1):99-112. PubMed ID: 22171779
[TBL] [Abstract][Full Text] [Related]
27. Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Elger T; Krajnak S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
Breast Cancer Res Treat; 2017 Sep; 165(2):293-300. PubMed ID: 28585074
[TBL] [Abstract][Full Text] [Related]
28. Integrating clinicopathologic and genomic tools in chemotherapy decision-making for early stage breast cancer.
Havard R; Henry NL
Future Oncol; 2017 Dec; 13(28):2507-2510. PubMed ID: 29168654
[No Abstract] [Full Text] [Related]
29. A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials.
Spears M; Yousif F; Lyttle N; Boutros PC; Munro AF; Twelves C; Pritchard KI; Levine MN; Shepherd L; Bartlett JM
Oncotarget; 2015 Oct; 6(31):31693-701. PubMed ID: 26372731
[TBL] [Abstract][Full Text] [Related]
30. An Integrative Approach for Identifying Network Biomarkers of Breast Cancer Subtypes Using Genomic, Interactomic, and Transcriptomic Data.
Firoozbakht F; Rezaeian I; D'agnillo M; Porter L; Rueda L; Ngom A
J Comput Biol; 2017 Aug; 24(8):756-766. PubMed ID: 28650678
[TBL] [Abstract][Full Text] [Related]
31. Is gene array testing to be considered routine now?
Paik S
Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
[TBL] [Abstract][Full Text] [Related]
32. Gene expression-based prognostic and predictive tools in breast cancer.
Munkácsy G; Szász MA; Menyhárt O
Breast Cancer; 2015 May; 22(3):245-52. PubMed ID: 25874688
[TBL] [Abstract][Full Text] [Related]
33. An integrated transcriptomic and computational analysis for biomarker identification in human glioma.
Xing W; Zeng C
Tumour Biol; 2016 Jun; 37(6):7185-92. PubMed ID: 26663173
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.
Liu YR; Jiang YZ; Xu XE; Hu X; Yu KD; Shao ZM
Clin Cancer Res; 2016 Apr; 22(7):1653-62. PubMed ID: 26813360
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
36. Intrinsic Subtypes of Primary Breast Cancer--Gene Expression Analysis.
Schmidt M; Thomssen C; Untch M
Oncol Res Treat; 2016; 39(3):102-10. PubMed ID: 27031354
[TBL] [Abstract][Full Text] [Related]
37. MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets.
Lemieux S; Sargeant T; Laperrière D; Ismail H; Boucher G; Rozendaal M; Lavallée VP; Ashton-Beaucage D; Wilhelm B; Hébert J; Hilton DJ; Mader S; Sauvageau G
Nucleic Acids Res; 2017 Jul; 45(13):e122. PubMed ID: 28472340
[TBL] [Abstract][Full Text] [Related]
38. Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis.
Manjili MH; Najarian K; Wang XY
Future Oncol; 2012 Jun; 8(6):703-11. PubMed ID: 22764768
[TBL] [Abstract][Full Text] [Related]
39. Prognostic gene expression signatures of breast cancer are lacking a sensible biological meaning.
Manjang K; Tripathi S; Yli-Harja O; Dehmer M; Glazko G; Emmert-Streib F
Sci Rep; 2021 Jan; 11(1):156. PubMed ID: 33420139
[TBL] [Abstract][Full Text] [Related]
40. Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes.
Chen J; Xu J; Li Y; Zhang J; Chen H; Lu J; Wang Z; Zhao X; Xu K; Li Y; Li X; Zhang Y
Oncotarget; 2017 Feb; 8(6):10171-10184. PubMed ID: 28052038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
